RecruitingPHASE1, PHASE2NCT06498648

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Studying Dedifferentiated liposarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Elise F Nassif, MD
University of Texas MD Anderson Cancer Center LAO
Intervention
Abemaciclib(drug)
Enrollment
74 enrolled
Eligibility
18 years · All sexes
Timeline
20262027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06498648 on ClinicalTrials.gov

Other trials for Dedifferentiated liposarcoma

Additional recruiting or active studies for the same condition.

See all trials for Dedifferentiated liposarcoma

← Back to all trials